Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Avanos Medical (AVNS) EBIT (2016 - 2025)

Avanos Medical's EBIT history spans 11 years, with the latest figure at $12.0 million for Q3 2024.

  • For Q3 2024, EBIT rose 900.0% year-over-year to $12.0 million; the TTM value through Sep 2024 reached $33.5 million, up 248.96%, while the annual FY2023 figure was $4.2 million, 88.17% down from the prior year.
  • EBIT for Q3 2024 was $12.0 million at Avanos Medical, up from $6.3 million in the prior quarter.
  • Across five years, EBIT topped out at $16.6 million in Q4 2022 and bottomed at -$47.2 million in Q4 2020.
  • The 5-year median for EBIT is $600000.0 (2020), against an average of -$1.8 million.
  • The largest YoY upside for EBIT was 3200.0% in 2021 against a maximum downside of 2166.67% in 2021.
  • A 5-year view of EBIT shows it stood at -$47.2 million in 2020, then surged by 52.54% to -$22.4 million in 2021, then soared by 174.11% to $16.6 million in 2022, then tumbled by 32.53% to $11.2 million in 2023, then grew by 7.14% to $12.0 million in 2024.
  • Per Business Quant, the three most recent readings for AVNS's EBIT are $12.0 million (Q3 2024), $6.3 million (Q2 2024), and $4.0 million (Q1 2024).